Two River Group

Two River Group is a New York-based venture capital firm and merchant bank specializing in the life science sector. The firm focuses on investments in biotechnology and related fields, aiming to develop preventive and therapeutic technologies across various disease areas, including oncology, cardiovascular disease, neurological disorders, and companion animal health care. Founded in September 2004 by partners Joshua Kazam, Peter Kash, David Tanen, and Benjamin Bernstein, Two River Group has established itself as a significant player in the life science investment landscape.

The firm's investment strategy emphasizes early to late-stage ventures, providing capital, operational support, and leadership to accelerate research and clinical development. Two River Group has a history of successful investments, including Allogene Therapeutics, which raised $324 million in an initial public offering on the NASDAQ in October 2018. The firm also participated in a $16.5 million Series A funding round for Hubble in March 2017, demonstrating its commitment to supporting innovative companies in the life science sector.

With offices in New York City and Los Angeles, Two River Group leverages its extensive experience and network to execute product development strategies, manage risk, and provide tailored support to its portfolio companies. The firm's unique approach aims to transform patient outcomes by fostering the growth of companies that develop groundbreaking therapies and technologies in the life science industry.